Semaglutide in Patients with Heart Failure with Preserved Ejection ...
WEBAug 25, 2023 · We conducted the Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial, a...
Semaglutide in Patients with Obesity-Related Heart Failure and …
WEBApr 6, 2024 · We conducted the STEP-HFpEF DM (Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction and Diabetes Mellitus) trial, a double-blind,...
Semaglutide versus placebo in patients with heart failure and …
WEBSep 7, 2024 · The SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials are registered at ClinicalTrials.gov, NCT03574597, NCT03819153, NCT04788511, and NCT04916470, respectively, and all are complete. Findings. Across the four trials, 3743 (16·8%) of 22 282 participants had a history of HFpEF (1914 assigned to semaglutide and 1829 assigned to placebo).
STEP-HFpEF: Body Weight Reduction With Semaglutide Greater in …
WEBJun 24, 2024 · Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of ...
Weight loss medication benefits patients with heart failure and …
WEBAug 25, 2023 · Semaglutide is a potent glucagon-like-peptide-1 receptor agonist which has previously been shown to produce substantial weight loss in people with overweight and obesity. 6 The STEP-HFpEF trial tested the hypothesis that treatment with semaglutide can significantly improve symptoms, physical limitations and exercise function, in addition to ...
Weight loss drug linked with reduced need for diuretics in heart ...
WEBMay 13, 2024 · The STEP-HFpEF and STEP-HFpEF DM trials evaluated once-weekly semaglutide treatment vs. placebo in patients with obesity-related HFpEF, without and with diabetes, respectively. 3,4 Both studies showed a significant improvement with semaglutide for heart failure symptoms, physical limitations, …
Novo Nordisk A/S: Wegovy® recommended by the European
WEB2 days ago · The primary objective of STEP HFpEF and STEP HFpEF-DM trials was to investigate the effects of subcutaneous semaglutide 2.4 mg once-weekly on symptoms, physical function, and body weight compared ...
STEP Up to Heart Failure: The STEP-HFpEF Trial
WEBDec 13, 2023 · Semaglutide Treatment Effect in People With Obesity and HFpEF (STEP-HFpEF) was a randomized control, double blinded study that assessed once weekly semaglutide in patients with HFpEF (left ventricular ejection fraction [LVEF] ≥45%) and a body mass index (BMI) ≥30 kg/m2 with New York Heart Association (NYHA) class II-IV symptoms. 1 In this ...
Semaglutide in Patients with Heart Failure with Preserved Ejection ...
WEBAug 25, 2023 · In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF Clinica ….
STEP-HFpEF: Semaglutide Improves Symptoms, Physical …
WEBAug 23, 2023 · In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, semaglutide improved heart failure-related symptoms and physical function, in addition to weight loss, based on findings from the STEP-HFpEF trial presented at ESC Congress 2023 and simultaneously published in the New England Journal of Medicine.